Please login to the form below

Not currently logged in
Email:
Password:

thyroid cancer

This page shows the latest thyroid cancer news and features for those working in and with pharma, biotech and healthcare.

RET rivals Loxo and Blueprint face off with early-stage data

RET rivals Loxo and Blueprint face off with early-stage data

with BLU-667 for at least 24 weeks, and 49% across all patients with that type of cancer. ... Existing treatment of medullary and papillary thyroid cancer with multi-kinase inhibitors is limited by frequent dose modifications or interruptions due to

Latest news

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    It has assumed greater importance for the targeted pipeline – which sits alongside AZ’s immuno-oncology R&D – since MEK Inhibitor selumetinib failed late-stage trials in thyroid cancer and lung ... National Cancer Institute (NCI) in the US, the

  • FDA gives Loxo breakthrough tag for second cancer drug FDA gives Loxo breakthrough tag for second cancer drug

    including patients with brain metastases, and a 45% response rate in thyroid cancer. ... said. “Given the many available therapies for NSCLC and medullary thyroid cancer, we are pleased that LOXO-292 has shown encouraging data in refractory patients,

  • Eisai’s Lenvima wins European liver cancer indication Eisai’s Lenvima wins European liver cancer indication

    It is now set as a first-line treatment for adults who have received no prior systemic therapy for advanced or unresectable hepatocellular carcinoma (HCC), a type of liver cancer that ... Lenvima however, is already on the European market to treat

  • New cancer drugs can’t quite plug the revenue hole at AZ New cancer drugs can’t quite plug the revenue hole at AZ

    There was one blip on the pipeline radar for AZ however, as it revealed in its interim update that thyroid cancer candidate selumetinib had failed a phase III trial in thyroid ... cancer. The MEK inhibitor had previously failed in a late-stage lung

  • Loxo, Bayer get quick FDA review for ‘precision’ cancer drug Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

    biomarker, a departure from the usual regulatory route of seeking approval based on the organ or tissue where the cancer starts to grow. ... NTRK fusions are seen in a broad range of tumour types, including various forms of colorectal, lung, thyroid,

More from news
Approximately 9 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal

  • EATRIS and the new age of partnering EATRIS and the new age of partnering

    In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... The first one we initiated in this matchmaking process was a bio-marker

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer. ... The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and

  • Pharma deals during August 2013 Pharma deals during August 2013

    In 2012 these drugs generated $289.6m in revenue for Onyx. Included in the Onyx clinical pipeline are sorafenib (in phase III for thyroid cancer) also partnered with Bayer and carfilzomib, ... This protracted process is indicative of the now “holy

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    III, this time for thyroid cancer. ... The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics